|
|
|
|
|
|
|
J Healthc Inf Manag 2010,Dec,21;24(1):57-63; (PMID: 20077927)
[...] experience, but a number of support issues must be addressed to ensure that patients have appropriate access to their health information. Two hundred and fifty breast cancer patients registered to use a portal providing access to personal health information over a six-week period.[...]
|
|
|
J Soc Integr Oncol 2010,Dec,21;8(1):14-9; (PMID: 20205985)
[...] practitioner, formed this university-based team to conceptualize and develop a prototype robotic device for reflexology for breast cancer patients. The nurse investigator contributed the intervention background and access to the population; the statistician guided the team thinking on factors that needed to be controlled for;[...]
|
|
|
J Soc Integr Oncol 2010,Dec,21;8(1):20-30; (PMID: 20205986)
[...]There are important safety concerns associated with dietary supplements and foods rich in phytoestrogens, especially for breast cancer patients with hormone-sensitive disease. However, no consensus has been reached concerning specific dietary items that should be avoided, and safe levels of potentially problematic foods have yet to be determined.[...]
|
|
|
Can Oncol Nurs J 2010,Dec,21;20(1):23-9; (PMID: 20369642)
Locally advanced breast cancer (LABC) occurs in 10% to 30% of all new primary breast cancer diagnoses. For reasons that are not well-understood, 20% to 30% of [...]
|
|
|
J Neuropsychiatry Clin Neurosci 2010,Dec,21;22(1):48-54; (PMID: 20160209)
The authors examined the long-term cognitive implications of cancer treatment among breast cancer survivors over 65 years old who received treatment during midlife. Thirty women survivors were matched with 30 noncancer, healthy older adults in terms of age, education, and IQ.[...]
|
|
|
MEDICC Rev 2010,Dec,21;12(1):36-40; (PMID: 20387333)
Clinical management of breast cancer, making a prognosis and deciding on treatment, currently depend on defining prognostic factors, especially hormone receptors (HR).[...]
|
|
|
J Pharm Biomed Anal 2010,Nov,02;53(3):228-34; (PMID: 20236782)
[...] and how the intratumoral concentration of PD 0332991 correlates with plasma PK parameters and molecular alterations in breast cancer tissues after PD 0332991 treatment. Before conducting such a clinical study, it is important to evaluate PD 0332991 levels in [...]
|
|
|
Appl Biochem Biotechnol 2010,Oct,01;162(3):912-25; (PMID: 19838861)
[...], Exserohilum turicicum, and Colectrotrichum cassiicola, at a concentration of 17.5 to 35 microg, and showed in vitro cytotoxicity against the BT474 breast cancer cell line with an IC(50) of approximately 21.2 microg.
|
|
|
Steroids 2010,Oct,01;75(10):625-31; (PMID: 20214913)
[...]2ME as a therapeutic agent were obtained by various clinical studies in patients with breast cancer and prostate cancer. However, one main problem appears to be the bioavailability of 2ME[...]
|
|
|
Cell Signal 2010,Oct,01;22(10):1536-42; (PMID: 20570726)
[...] and induce the proteasomal degradation of this enzyme in human pulmonary artery smooth muscle cells, MCF-7 breast cancer cells and androgen-independent LNCaP-AI prostate cancer cells. Proteasomal degradation of SK1 in response to FTY720[...]
|
 1 2 3 4 5 6 7 8 
|
|
|
|
|
